Tech Company Financing Transactions
ReCode Therapeutics Funding Round
Cystic Fibrosis Foundation participated in a funding round for ReCode Therapeutics. The round was announced by the company on 8/6/2026.
Transaction Overview
Company Name
Announced On
8/6/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to support its research collaboration with a gene editing partner to develop a novel gene editing therapy designed to correct mutations in the CFTR gene, the underlying genetic cause of cystic fibrosis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1455 Adams Dr.
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Website
Email Address
Overview
ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases with significant unmet medical need. ReCode's diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Lockhart
Browse more venture capital transactions:
Prev: 8/6/2026: Acrab venture capital transaction
Next: 8/6/2026: SkinBit venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs